https://www.selleckchem.com/pr....oducts/pf-07265807.h
02) and 3 in those with hyperleukocytosis (≥ 50,000/μl) (p = 0.002). CONCLUSION MGA allowed tailored post-consolidation in 53.8% of patients after high-dose aracytin induction, with long-term survival doubling that reported in the literature after standard-dose cytarabine regimens. TRIAL REGISTRATION The study was registered with the Umin Clinical Trial Registry (www.umin.ac.jp/ctr), number R000014052.PURPOSE To evaluate short and long-term effects of a multifactorial and multidisciplinary in-patient municipality intervention includ
Like
Comment
Share
